Founders of Singapore rubbish collector 800 Super close to deal to sell business

AstraZeneca PLC (AZNCF)

Other OTC - Other OTC Delayed Price. Currency in USD

Add to watchlist

134.13

+2.59

(+1.97%)

At close: 03:41PM EDT

Loading interactive chart…

Financial Times
AstraZeneca sues former executive over move to rival GSK
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
Zacks
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Business Wire
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
WILMINGTON, Del., August 16, 2022--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).